The concept of “Growth at a Reasonable Price,” or GARP, represents a middle path in equity investing. It seeks companies that demonstrate strong earnings and revenue expansion but are not trading at the sky-high multiples often associated with pure growth stocks. By focusing on firms that combine solid fundamental health with a valuation that hasn’t yet run away from reality, GARP investors aim to capture upside potential without assuming excessive risk. One fundamental screen that operationalizes this strategy is the “Affordable Growth” filter, which specifically targets securities with a growth rating above 7, a valuation score above 5, and decent profitability and health scores. This approach helps narrow the field to candidates that are both expanding and reasonably priced.
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) has emerged from such a screen, and a closer look at its full fundamental analysis report reveals why this is a strong candidate for investors seeking affordable growth. The company, a commercial-stage biopharmaceutical firm focused on rare diseases, currently holds a composite fundamental rating of 8 out of 10, placing it well above the average in the highly volatile Biotechnology industry.
Growth Metrics: Strong Past Performance and Promising Forward Estimates
For a GARP strategy, growth is non-negotiable, and CPRX scores highly here. The company’s ChartMill Growth rating stands at 8 out of 10, supported by both historical momentum and forward-looking estimates. Over the past year, earnings per share grew by a healthy 10.83%, while the five-year average EPS growth rate is an impressive 32.75% annually. Revenue has followed a similar trajectory, with 11.65% growth in the last year and a five-year compound annual growth rate of 37.67%.
More importantly for future-oriented investors, the growth story is not fading. Analysts project EPS will expand by an average of 25.46% per year over the coming years, with revenue growth expected to remain solid at nearly 10% annually. While the rate of growth is slightly slowing from the rapid pace of the past half-decade, the direction remains firmly positive. This combination of proven historical expansion and credible forward guidance is exactly what the Affordable Growth screen is designed to capture.
Valuation: Reasonably Priced Relative to Growth
The second pillar of the GARP approach is valuation, and here CPRX presents a mixed but ultimately favorable picture. The company’s Valuation rating is 7 out of 10. While its trailing Price/Earnings ratio of 18.09 might appear somewhat elevated in isolation, context is everything. Within the Biotechnology industry, CPRX is actually valued cheaper than 95.7% of its peers. Furthermore, the stock’s Price/Forward Earnings ratio of 13.84 is significantly lower than both the industry average of 31.82 and the S&P 500 average of 21.33.
This gap between the current P/E and the forward P/E highlights the expected acceleration in earnings. The PEG ratio, which adjusts the P/E for future growth, indicates that the current valuation is fair. In short, investors are not paying a premium for the growth story—they are getting it at a price that aligns with the company’s earnings trajectory. This is the hallmark of an affordable growth stock.
Profitability and Health: A Strong Foundation
A growth stock is only interesting if the company can sustain that growth without crumbling under financial strain. CPRX’s Profitability rating of 9 out of 10 is among the best in its industry. The company reports a Return on Equity of 21.85%, a Return on Invested Capital of 19.95%, and a profit margin of 37.08%—each ranking in the top 5% of the industry. Furthermore, both operating and gross margins are strong, with operating margin showing steady improvement over recent years.
Equally important, the company’s Health rating is 8 out of 10, driven by zero outstanding debt. With a current ratio of 7.10 and an Altman Z-Score of 19.91, there is no liquidity concern whatsoever. This financial strength means CPRX can invest in its pipeline and commercial operations without the burden of a heavy debt load. For the GARP investor, this is critical: strong health and profitability mean the growth is built on a sustainable platform, not on borrowing or questionable practices.
Analyst Views and Market Context
With the broader S&P 500 trending positively over both the long and short term, the current market environment is generally supportive of growth-oriented strategies. Analyst estimates for CPRX point to continued expansion, reinforcing the screen’s output. The combination of a reasonably priced valuation, solid growth expectations, and excellent financial health makes CPRX a textbook example of a stock that fits the Affordable Growth profile.
Investors looking for similar opportunities can explore more stocks that pass this disciplined combination of filters. For a complete list of companies exhibiting strong growth, decent valuation, and solid financial health, check out the full Affordable Growth screen results here.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Always conduct your own research and consider your financial situation before making investment decisions.
Read full article here »
View the Zacks #1 Rank List
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Textbook GARP Stock Delivering Affordable Growth
The concept of “Growth at a Reasonable Price,” or GARP, represents a middle path in equity investing. It seeks companies that demonstrate strong earnings and revenue expansion but are not trading at the sky-high multiples often associated with pure growth stocks. By focusing on firms that combine solid fundamental health with a valuation that hasn’t yet run away from reality, GARP investors aim to capture upside potential without assuming excessive risk. One fundamental screen that operationalizes this strategy is the “Affordable Growth” filter, which specifically targets securities with a growth rating above 7, a valuation score above 5, and decent profitability and health scores. This approach helps narrow the field to candidates that are both expanding and reasonably priced.
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) has emerged from such a screen, and a closer look at its full fundamental analysis report reveals why this is a strong candidate for investors seeking affordable growth. The company, a commercial-stage biopharmaceutical firm focused on rare diseases, currently holds a composite fundamental rating of 8 out of 10, placing it well above the average in the highly volatile Biotechnology industry.
Growth Metrics: Strong Past Performance and Promising Forward Estimates
For a GARP strategy, growth is non-negotiable, and CPRX scores highly here. The company’s ChartMill Growth rating stands at 8 out of 10, supported by both historical momentum and forward-looking estimates. Over the past year, earnings per share grew by a healthy 10.83%, while the five-year average EPS growth rate is an impressive 32.75% annually. Revenue has followed a similar trajectory, with 11.65% growth in the last year and a five-year compound annual growth rate of 37.67%.
More importantly for future-oriented investors, the growth story is not fading. Analysts project EPS will expand by an average of 25.46% per year over the coming years, with revenue growth expected to remain solid at nearly 10% annually. While the rate of growth is slightly slowing from the rapid pace of the past half-decade, the direction remains firmly positive. This combination of proven historical expansion and credible forward guidance is exactly what the Affordable Growth screen is designed to capture.
Valuation: Reasonably Priced Relative to Growth
The second pillar of the GARP approach is valuation, and here CPRX presents a mixed but ultimately favorable picture. The company’s Valuation rating is 7 out of 10. While its trailing Price/Earnings ratio of 18.09 might appear somewhat elevated in isolation, context is everything. Within the Biotechnology industry, CPRX is actually valued cheaper than 95.7% of its peers. Furthermore, the stock’s Price/Forward Earnings ratio of 13.84 is significantly lower than both the industry average of 31.82 and the S&P 500 average of 21.33.
This gap between the current P/E and the forward P/E highlights the expected acceleration in earnings. The PEG ratio, which adjusts the P/E for future growth, indicates that the current valuation is fair. In short, investors are not paying a premium for the growth story—they are getting it at a price that aligns with the company’s earnings trajectory. This is the hallmark of an affordable growth stock.
Profitability and Health: A Strong Foundation
A growth stock is only interesting if the company can sustain that growth without crumbling under financial strain. CPRX’s Profitability rating of 9 out of 10 is among the best in its industry. The company reports a Return on Equity of 21.85%, a Return on Invested Capital of 19.95%, and a profit margin of 37.08%—each ranking in the top 5% of the industry. Furthermore, both operating and gross margins are strong, with operating margin showing steady improvement over recent years.
Equally important, the company’s Health rating is 8 out of 10, driven by zero outstanding debt. With a current ratio of 7.10 and an Altman Z-Score of 19.91, there is no liquidity concern whatsoever. This financial strength means CPRX can invest in its pipeline and commercial operations without the burden of a heavy debt load. For the GARP investor, this is critical: strong health and profitability mean the growth is built on a sustainable platform, not on borrowing or questionable practices.
Analyst Views and Market Context
With the broader S&P 500 trending positively over both the long and short term, the current market environment is generally supportive of growth-oriented strategies. Analyst estimates for CPRX point to continued expansion, reinforcing the screen’s output. The combination of a reasonably priced valuation, solid growth expectations, and excellent financial health makes CPRX a textbook example of a stock that fits the Affordable Growth profile.
Investors looking for similar opportunities can explore more stocks that pass this disciplined combination of filters. For a complete list of companies exhibiting strong growth, decent valuation, and solid financial health, check out the full Affordable Growth screen results here.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Always conduct your own research and consider your financial situation before making investment decisions.
Read full article here »